ORYZON to Regain Rights to ORY-1001 (RG6016)
BARCELONA, SPAIN and CAMBRIDGE MA.
• Management to Host two Web Conferences today, July 20th
- at 10:00 am CET in Spanish and
- at 8:30 am ET in English
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that yesterday evening Roche informed Oryzon that due to a portfolio prioritization, it has decided to discontinue its involvement in the clinical development of the investigational Lysine Specific Demethylase-1 (LSD1) inhibitor ORY-1001 (RG6016) for the treatment of patients with acute myeloid leukemia (AML) and solid tumors pursuant to the license agreement between Oryzon and Roche dated April 1st, 2014.